Search research articles
Contact Us
Filters
Showing results (31-40 of 38) with videos related to
Page
of 4
Sort By:
You have reached the last page of results.
This site can display upto 38 results.
Cancer
|
August 14, 2025
Lenvatinib plus pembrolizumab for patients with previously treated select solid tumors: Results from the phase 2 LEAP-005 study recurrent glioblastoma cohort
Sun Young Rha, Eduardo Castanon, Sanjeev Gill, et al.
Elife
|
July 5, 2022
Genomic landscape of lymphatic malformations: a case series and response to the PI3Kα inhibitor alpelisib in an <i>N</i>-of-1 clinical trial
Montaser F Shaheen, Julie Y Tse, Ethan S Sokol, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 18, 2025
Large-Scale Multiomic Analysis Identifies Anatomic Differences and Immunogenic Potential in Subtypes of Leiomyosarcoma
Galina Lagos, Roman Groisberg, Andrew Elliott, et al.
Cancer Research Communications
|
February 26, 2026
Lenvatinib Plus Pembrolizumab for Patients With Previously Treated Advanced Gastric, Biliary Tract, or Pancreatic Cancer: Results From the Phase 2 LEAP-005 Study
Mariano Ponz-Sarvisé, Sun Young Rha, Carlos A Gomez-Roca, et al.
Nature Reviews. Clinical Oncology
|
March 16, 2021
COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials
Aakash Desai, Justin F Gainor, Aparna Hegde, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 13, 2022
BAMM (BRAF Autophagy and MEK Inhibition in Melanoma): A Phase I/II Trial of Dabrafenib, Trametinib, and Hydroxychloroquine in Advanced BRAFV600-mutant Melanoma
Janice M Mehnert, Tara C Mitchell, Alexander C Huang, et al.
Cancer
|
February 7, 2025
Olaparib in treatment-refractory isocitrate dehydrogenase 1 (IDH1)- and IDH2-mutant cholangiocarcinoma: Safety and antitumor activity from the phase 2 National Cancer Institute 10129 trial
Michael Cecchini, Mary Jo Pilat, Nataliya Uboha, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 26, 2023
Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket Study
Yoshiaki Nakamura, Nobumasa Mizuno, Yu Sunakawa, et al.
Page
of 4
Search research articles
Search
Showing results (31-40 of 38) with videos related to
Sort By:
Page
of 4
You have reached the last page of results.
This site can display upto 38 results.
Cancer
|
August 14, 2025
Lenvatinib plus pembrolizumab for patients with previously treated select solid tumors: Results from the phase 2 LEAP-005 study recurrent glioblastoma cohort
Sun Young Rha, Eduardo Castanon, Sanjeev Gill, et al.
Elife
|
July 5, 2022
Genomic landscape of lymphatic malformations: a case series and response to the PI3Kα inhibitor alpelisib in an <i>N</i>-of-1 clinical trial
Montaser F Shaheen, Julie Y Tse, Ethan S Sokol, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 18, 2025
Large-Scale Multiomic Analysis Identifies Anatomic Differences and Immunogenic Potential in Subtypes of Leiomyosarcoma
Galina Lagos, Roman Groisberg, Andrew Elliott, et al.
Cancer Research Communications
|
February 26, 2026
Lenvatinib Plus Pembrolizumab for Patients With Previously Treated Advanced Gastric, Biliary Tract, or Pancreatic Cancer: Results From the Phase 2 LEAP-005 Study
Mariano Ponz-Sarvisé, Sun Young Rha, Carlos A Gomez-Roca, et al.
Nature Reviews. Clinical Oncology
|
March 16, 2021
COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials
Aakash Desai, Justin F Gainor, Aparna Hegde, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 13, 2022
BAMM (BRAF Autophagy and MEK Inhibition in Melanoma): A Phase I/II Trial of Dabrafenib, Trametinib, and Hydroxychloroquine in Advanced BRAFV600-mutant Melanoma
Janice M Mehnert, Tara C Mitchell, Alexander C Huang, et al.
Cancer
|
February 7, 2025
Olaparib in treatment-refractory isocitrate dehydrogenase 1 (IDH1)- and IDH2-mutant cholangiocarcinoma: Safety and antitumor activity from the phase 2 National Cancer Institute 10129 trial
Michael Cecchini, Mary Jo Pilat, Nataliya Uboha, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 26, 2023
Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket Study
Yoshiaki Nakamura, Nobumasa Mizuno, Yu Sunakawa, et al.
Page
of 4